Skip to main content
SpringerLink
Log in

A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma

  • Guest editor's introduction
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Epidermal growth factor receptor (EGFR) is a potentially useful new biological prognostic and predictive indicator in human breast cancer. Additional research on EGFR is warranted to enhance our information on: i) the method of choice for its detection and quality control issues; ii) its association with novel pathobiological markers of prognosis; iii) its prognostic value in multivariate analysis; and iv) its capability to predict response to hormone therapy and, in the future, to biological treatments using antibodies against the specific receptor or its ligands.

In the present study we update previous data on EGFR status, determined immunocytochemically, by prolonging the period of observation up to 5 years and by including, in the multivariate analysis, several new biological indicators. The main results obtained are: i) EGFR is weakly associated with Ki-67 score (p=0.073) and with p53 expression (p=0.06); ii) EGFR is a significant indicator for recurrence (p<0.01 and odds ratio of 2.82) but not for death (p=0.27 and odds ratio of 1.49); iii) the prognostic power of EGFR is enhanced when combined with the knowledge of S-phase fraction; and iv) in multivariate analysis on relapse-free survival, EGFR and S-phase fraction (likelihood ratio test=26.40; p<0.01), c-erbB-2 protein and p53 mutant protein expression (likelihood ratio test= 5.94; p=0.05), cathepsin D (likelihood ratio test= 9.78; p<0.01), and nodal status (likelihood ratio test= 7.32; p<0.01) are significant and independent prognostic factors in early-stage breast carcinoma.

This new information could be of help for a more rational approach in the use of EGFR as a marker in future clinical research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fentiman IS, Mansel RE: The axilla: not a no-go zone. Lancet i:221–223, 1991

    Google Scholar 

  2. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F: Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 16:127–133, 1990

    Google Scholar 

  3. Gasparini G, Pozza F, Harris AL: Evaluating usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206–1219, 1993

    Google Scholar 

  4. Carpenter G, Cohen S:125I-labeled human epidermal growth factor: binding, internalization, and degradation in human fibroblasts. J Cell Biol 71:159–171, 1976

    Google Scholar 

  5. Hunter T, Cooper JA: Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A-431 human tumour cells. Cell 24:741–752, 1981

    Google Scholar 

  6. Cohen S, Elliott GA: The stimulation of epidermal keratinisation by a protein isolated from the submaxillary gland of the mouse. J Invest Dermatol 40:1–5, 1963

    Google Scholar 

  7. Carpenter G, Lembach KJ, Morrison MM, Cohen S: Characterization of the binding of125I-labeled epidermal growth factor to human fibroblasts. J Biol Chem 250:4297–4304, 1975

    Google Scholar 

  8. Stoschek CM, King LE: Role of the epidermal growth factor in carcinogenesis. Cancer Res 46:1030–1035, 1986

    Google Scholar 

  9. Sporn MB, Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med 303:878–880, 1980

    Google Scholar 

  10. Roos W, Fabbro D, Kung W, Costa SD, Eppenberger U: Correlation between hormone dependency and the regulation of epidermal growth factor receptor by tumor promoters in human mammary carcinoma cells. Proc Natl Acad Sci USA 83:991–995, 1986

    Google Scholar 

  11. Downward J, Parker P, Waterfield MD: Autophosphorylation sites on the epidermal growth factor receptor. Nature 311:483–486, 1984

    Google Scholar 

  12. Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226–229, 1986

    Google Scholar 

  13. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocrine Rev 13:3–17, 1992

    Google Scholar 

  14. Sainsbury JRC, Needham GK, Farndon JR, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i:1398–1402, 1987

    Google Scholar 

  15. Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146–151, 1991

    Google Scholar 

  16. Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CHW: Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087–2090, 1989

    Google Scholar 

  17. Foekens JA, Portengen H, Van Putten WLJ, Trapman AMAC, Reubi JC, Alexieva-Figusch H, Klijn JGM: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009, 1989

    Google Scholar 

  18. Lewis S, Locker A, Todd JH, Bell JA, Nicholson S, Elston CW, Blamey RW, Ellis IO: Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43:385–391, 1990

    Google Scholar 

  19. Gasparini G, Bevilacqua P, Pozza F, Meli S, Boracchi P, Marubini E, Sainsbury JRC: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 66:970–976, 1992

    Google Scholar 

  20. Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JRC, Meli S, Boracchi P, Testolin A, La Malfa G, Pozza F: Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686–695, 1992

    Google Scholar 

  21. Nicholson J, Halcrow P, Farndon JR, Sainsbury JRC, Chambers P, Harris AL: Expression of epidermal growth factor receptor associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i:182–185, 1989

    Google Scholar 

  22. Workman P, D'Incalci M, Berdel WE, Egorin MJ, Helene C, Hickman JA, Jarman M, Schwartsmann G, Sikora K: New approaches in cancer pharmacology: Drug design and development. Eur J Cancer 28A:1190–1200, 1992

    Google Scholar 

  23. Waterfield MD, Mayers ELV, Stroobant P, Bennet PLP, Young S, Goodfellow PN, Banting GS, Ozanne B: A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem 20:149–161, 1982

    Google Scholar 

  24. Hsu SM, Raine L, Fanger H: A comparative study of the peroxidase method and an avidin-biotin-complex method for studying polypeptide hormones with radio-immunoassay antibodies. Am J Clin Pathol 75:734–738, 1981

    Google Scholar 

  25. Bevilacqua P, Gasparini G, Dal Fior S, Corradi G: Immunocytochemical determination of epidermal growth factor receptor with monoclonal EGFR1 antibody in primary breast cancer patients. Oncology 47:313–317, 1990

    Google Scholar 

  26. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P: p53 and c-erbB-2 protein expression in breast carcinomas. Am J Clin Pathol 98:408–418, 1992

    Google Scholar 

  27. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887, 1992

    Google Scholar 

  28. Benzecri JP: L'analyze des donnes. Dunod, Paris, 1973

    Google Scholar 

  29. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83: 154–155, 1991

    Google Scholar 

  30. Weidner N, Gasparini G: Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients. Breast Cancer Res Treat 29:97–107, 1994

    Google Scholar 

  31. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845- 855, 1992

    Google Scholar 

  32. Isola J, Visakorpi T, Holli K, Kallioniemi O-P: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109–1114, 1992

    Google Scholar 

  33. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200–206, 1993

    Google Scholar 

  34. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, Kallioniemi O-P: Cathepsin D expression detected by immunocytochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 11:36–43, 1993

    Google Scholar 

  35. Gasparini G, Bevilacqua P, Meli S, Bolzicco GP, Cazzavillan S, La Malfa G, Marubini E, Pozza F: Immunocytochemical determination of pro-cathepsin D: A significant and independent prognostic indicator in early-stage breast cancer. Breast Disease 6:85–97, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Bortolo Regional Medical Centre, Vicenza, Italy

    Giampietro Gasparini, Pierantonio Bevilacqua & Franco Pozza

  2. Institute of Medical Statistics and Biometry, University of Milan, National Cancer Institute of Milan, Italy

    Patrizia Boracchi & Maura Mezzetti

  3. Dept. of Pathology, University of California, San Francisco, CA, USA

    Noel Weidner

Authors
  1. Giampietro Gasparini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrizia Boracchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierantonio Bevilacqua
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maura Mezzetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Franco Pozza
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Noel Weidner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gasparini, G., Boracchi, P., Bevilacqua, P. et al. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res Tr 29, 59–71 (1994). https://doi.org/10.1007/BF00666182

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00666182

Key words

Search

Navigation